Skip to main content
. 2014 Dec 23;60(5):1457–1464. doi: 10.1007/s10620-014-3486-7
Author Employment Stock ownership Consultancy Honoraria Research grant Paid expert testimony Other
MB Bristol-Myers Squibb; Gilead Bristol-Myers Squibb; Gilead
NT AbbVie; Gilead; Janssen AbbVie; Bayer; Bristol-Myers Squibb; Gilead; Janssen; Merck; Roche; Salix AbbVIe; Beckman; Bristol-Myers Squibb; Gilead; Janssen; Roche; Vertex
JP Abbott; AbbVie; Bristol-Myers Squibb; Boehringer; Gilead; GlaxoSmithKline; Kedrion; Janssen; Merck; Merck Sharp & Dohme; Novartis, Roche Bristol-Myers Squibb; Novartis; Roche Abbott; Bristol-Myers Squibb; Boehringer; Gilead; Kedrion; Janssen; Merck; Merck Sharp & Dohme; Novartis; Roche
RF AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Merck; Novartis; Roche AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Merck; Novartis; Roche Roche
SG AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Merck Sharp & Dohme; Roche AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Merck Sharp & Dohme; Roche
ZK Gilead; Idenix; Jansen; Novartis; Receptos; Roche
RAS Gilead Gilead
JFF Gilead Gilead
EBM Gilead Gilead
PC Gilead Gilead
KMK Gilead Gilead
GMS Gilead Gilead
EG Achillion; Gilead; Idenix; Janssen; Merck; Novartis; Novira; Roche
PM Abbott; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead; Janssen/Tibotec; Merck; Novartis; Pfizer; Roche; Vertex Bristol-Myers Squibb; Gilead; Janssen/Tibotec; Merck; Novartis; Roche